Strensiq astrazeneca patent?

Does Strensiq (asfotase alfa) have a patent linked to AstraZeneca?

Strensiq is a product of Kyowa Kirin. AstraZeneca is not listed here as the patent holder for Strensiq or as the company whose patents protect the drug. So, there is no basis in the provided information to connect a “Strensiq AstraZeneca patent” to how Strensiq is protected.

If you meant a different AstraZeneca product or a different spelling/company name, tell me which one and I can narrow the patent question to that asset.

When would Strensiq patents typically expire (and what affects the date)?

Patent expiry dates for medicines are usually driven by:
- the original patent filing and any patent term adjustments,
- country-specific filings (expiry can differ by jurisdiction),
- possible secondary patents (reformulations, new uses, manufacturing/process),
- exclusivity regimes that can extend market protection beyond primary patent expiry.

The exact expiry date for Strensiq depends on the specific patent family, jurisdiction, and whether you’re looking at a primary patent, a secondary patent, or regulatory exclusivity.

Are there exclusivity periods that could block generic or biosimilar entry even after patent expiry?

For biologics, the practical timeline often involves both:
- patent coverage (which can stop copycats directly), and
- regulatory exclusivity or data protection (which can limit approval/marketing timing).

The actual “can a competitor launch when” timeline requires matching the patent/exclusivity dates to the country of interest.

Which country’s patent/exclusivity should you check for Strensiq?

Patent status and expiry depend on where you’re located. If you share the country (US, EU, UK, Canada, etc.), the asset name (what exactly you mean by “AstraZeneca patent”), and whether you mean “when does it expire” or “who owns it,” I can give a more precise answer based on the relevant legal records.

---

Sources

No sources were provided in the prompt content, so no citations are available.